Astria Therapeutics Inc

NASDAQ: ATXS
$10.17
+$0.60 (+6.3%)
Closing price May 9, 2024

ATXS Chart and Intraday Price

ATXS Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address ONE KENDALL SQUARE, BLDG. 1400E, SUITE B14202, CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 818.90M USD
Shares Outstanding 54,666,000
Astria Therapeutics, Inc. is a Boston-based biopharmaceutical firm dedicated to developing treatments for rare and specialized allergic and immunological diseases. Its flagship project, STAR-0215, is a pioneering monoclonal antibody aimed at treating hereditary angioedema, currently in the clinical trial phase. Originally known as Catabasis Pharmaceuticals, Astria rebranded in 2021, continuing its mission since its inception in 2008 to address unmet medical needs in niche disease areas.

ATXS Articles

Another Huge Buffett Purchase Highlights Recent Insider Buying
Another huge Warren Buffett purchase highlighted the past week's insider buying, and a couple of IPOs also prompted insiders to action.
Trey Thoelcke
Published:

Here's What Insiders Are Buying to Wrap Up the Year
As the year wound to a close, the most notable insider buying was focused on biotech stocks, but an oil and gas company CEO also returned to the buy window.
Trey Thoelcke
Published: